Study shows who survives Burkitt lymphoma

August 8, 2013

A new study in the journal Cancer that tracked survival of more than 2,200 adults over the last decade with a highly aggressive form of lymphoma finds that with notable exceptions, medicine has made substantial progress in treating them successfully. To help doctors and researchers better understand who responds well to treatment and who doesn't, the study authors used their findings to create a stratified risk score of patient prognosis.

Burkitt Lymphoma is not a common lymphoma but it is especially aggressive. The apparent progress doctors have made over the last two decades has come, unlike with many other cancers, with little guidance about how to treat different patients or what outcomes to expect. The same regimen of intensive chemotherapy and the monoclonal antibody rituximab are recommended for most patients.

"There was little available for Burkitt lymphoma in terms of , indicators or scoring," said Dr. Jorge Castillo, an Assistant Professor of Medicine at the Warren Alpert Medical School of Brown University and a /oncology specialist at Rhode Island Hospital. He's the lead author of the study, which first appeared online July 30.

Castillo wanted to better understand the prognosis of patients, so he and his co-authors looked at 11 years of in the Surveillance, Epidemiology and End Results (SEER) database, which keeps patient demographic and outcomes data from 18 areas around the country. They analyzed survival rates among 2,284 patients by factors including age, race, stage of the cancer at diagnosis, and in what region of the body the cancer struck.

What they found is that while survival rates have risen substantially overall, outcomes have not improved much for patients who are older than 60, black, or whose cancer is diagnosed at a late stage. They used these to create a simple new risk score that allowed them to make meaningful distinctions about prognosis. Patients with the lowest score had a better than 7 in 10 chance of survival with treatment, while those with the highest score have a less than 3 in 10 chance of surviving.

Improved survival, for most.

Age makes a big difference in survival, Castillo and his co-authors found. Their analysis yielded the calculation that patients over 80 years old have nearly 5 times the risk of dying from the cancer as people aged 20-39. Patients aged 60-79 had twice the risk of dying as the youngest patients and those aged 40-59 had a risk 1.5 times greater than those aged 20-39.

Risk of death climbed similarly with the stage of cancer. Stage IV patients had a 2.4 times greater risk of dying than those at Stage I. Stage III patients had a 1.5 times greater risk.

Race was also a factor, although to a more mild degree. Hispanics and whites had similar risk levels but black people, who were 9.3 percent of the patients, had a 1.6 times higher risk of death.

These same risk factors are also evident in whether patients have seen improved survival over time, for instance as and later have gained prevalence.

In 1998, the survival rate was fairly uniform for all age groups, Castillo and his colleagues found: 34.7 percent overall. As of 2007, survival had risen to 62.1 percent for the youngest adult patients, but patients over 60 have only drifted slightly upward to a survival rate of 43.5 percent.

Among patients of different ethnic backgrounds, there is a similarly widening gap: Survival among non-Hispanic whites rose from 31.7 percent to 50.9 percent and among Hispanics from 22.7 percent to 47.1 percent. Among blacks, however, survival has remained low and flat: from 28.8 percent in 1998 to only 29.9 percent in 2007.

Castillo said he does not know with certainty from the study or from the medical literature why blacks fare relatively poorly, but in his study he was able to control for socioeconomic status and the disparity was independent of it.

Prognostic score

Using the significant risk factors they discovered, Castillo and co-authors Dr. Eric Winer, also of RIH and Dr. Adam Olszewski of Memorial Hospital in Pawtucket created the in which an age 40-59 or being black adds 1 point, being age 60 to 79 or stage III or IV adds two points, and age over 80 adds 4 points. Doing so separated the 2,284 patients into roughly equal groups with a wide range of 5-year relative (relative to the likelihood of survival of a similar person without the disease).

Among the groups those with a score of 0 to 1 had a 71 percent relative survival rate. A score of 2 reduced the rate to 55 percent, a score of 3 had a 41 percent relative survival and for those at 4 or higher the rate was merely 29 percent.

Castillo said there are several applications of the score, including helping doctors, and their families understand what to expect, and to evaluate whether intensive regimens of difficult therapy are truly desirable, compared to possible alternatives. The score can also inform researchers about how to design clinical trials of treatments of the disease.

"It helps to identify people who don't benefit from what we're doing right now," he said.

But thankfully for many people, care appears to be working.

Explore further: Difference in breast cancer survival between black and white women has not changed substantially

Related Stories

Difference in breast cancer survival between black and white women has not changed substantially

July 23, 2013
In an analysis of 5-year survival rates among black and white women diagnosed with breast cancer between 1991 and 2005, black women continued to have a lower rate of survival, with most of the difference related to factors ...

Radioimmunotherapy could extend lives of advanced lymphoma patients

June 11, 2013
A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy (RIT) may become the most powerful cancer-killing therapy available, with the hope that patients' lymphoma ...

Obese kidney failure patients receive survival benefit from transplantation

July 25, 2013
Most obese individuals with kidney failure can prolong their lives by receiving a kidney transplant, although this survival benefit is lower in severely obese individuals. That's the conclusion of a new study published in ...

Nonsentinel lymph nodes key factor in melanoma prognosis

August 2, 2013
(HealthDay)—Nonsentinel lymph node (NSLN) positivity is a significant prognostic factor in patients with stage III melanoma, associated with shorter overall and disease-specific survival, according to research published ...

Black patients with kidney cancer have poorer survival than whites

November 12, 2012
Among patients with the most common form of kidney cancer, whites consistently have a survival advantage over blacks, regardless of patient and tumor characteristics or surgical treatment. That is the conclusion of a new ...

Death rate higher in minorities with acute leukemia

September 19, 2011
Blacks and Hispanics have fewer cases of acute leukemia compared to whites but they die at a substantially higher rate, according to study results presented at the Fourth AACR Conference on The Science of Cancer Health Disparities, ...

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.